No specific symptoms or signs have been identified following acute overdose with RETROVIR, apart from those listed as undesirable effects such as fatigue, headache, vomiting, and occasional reports of haematological disturbances. Following a report where a patient took an unspecified quantity of RETROVIR, blood zidovudine levels were over sixteen times the normal therapeutic level, but there were no short term clinical, biochemical or haematological sequelae identified.
Patients should be observed closely for evidence of toxicity (see Adverse Reactions) and given the necessary supportive therapy.
Haemodialysis and peritoneal dialysis appear to have a limited effect on elimination of zidovudine but enhance the elimination of the glucuronide metabolite.
IV infusion: Dosages as high as 7.5 mg/kg by infusion every four hours for two weeks have been administered to five patients. One patient experienced an anxiety reaction while the other four had no untoward effects.